top of page
Recent Research
NOVN: Ianalumab’s unique Sjögren’s data, likely first
Ianalumab is well placed to be the first treatment to enter the notoriously challenging Sjögren’s syndrome, with its unique data endowing it with credibility for phase III in this indication, which has been fraught with failures in a field of three competitors with otherwise similar data.
Dec 11, 2024
NOVN: Consensus missing large Fabhalta upside
The market continues to underestimate Fabhalta's prospects from current and potential indications. The recent positive APPULSE trial...
Dec 11, 2024
NOVN/AMGN: Cholesterol-busting Lipoprotein (a) drugs likely to lead to new multibillion cardiovascular breakthrough
NOVN lipoprotein (a) cholesterol-lowering pelacarsen is likely to be the first cardiovascular breakthrough in decades by reducing an...
Dec 11, 2024
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page